🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Bio-Techne Corporation TECH SPX

Healthcare · Biotechnology · United States
https://www.bio-techne.com

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

READ MORE ›
$51.68
+7.42% 1Y

Market & Price

Market Cap
$8.09B
Current Price
$51.68
High / Low (52W)
$71.15 / $43.22
Beta
1.41

Valuation

Stock P/E
73.83
Industry PE
23.65
Forward P/E
25.06
PEG Ratio
0.70
Book Value
$12.90
Price to Book
4.01
P/S
6.68
EV/EBITDA
22.31
Dividend Yield
0.62%

Profitability & Returns

ROCE
4.49%
ROE
5.34%
ROA
7.45%
Profit Margin
9.05%
Op Margin
25.19%
EPS (Latest Qtr)
$0.32
EPS (TTM)
$0.70

Balance Sheet & Liquidity

Debt/Equity
0.14
Quick Ratio
2.80
Current Ratio
4.49
Debt
$290.32M
Total Assets
$2.56B
Current Assets
$608.30M
Working Capital
$432.45M

Ownership

Promoter Holding
0.30%
Chg in Prom Hold
-
FII / Inst Holding
117.81%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$8.17B
Total Revenue (TTM)
$1.21B
EBITDA
$366.04M
Free Cash Flow
$299.85M
Operating Cash Flow
$294.86M
Shares Outstanding
156.57M
Gross Margin
66.40%
Payout Ratio
45.71%

Growth (CAGR)

Revenue 5Y
3.33%
Profit 5Y
-35.38%
Revenue (YoY)
-1.50%
Earnings (YoY)
128.60%

PROS

  • Generates positive free cash flow.

CONS

  • Trading at a high P/E of 73.8.
  • Earnings shrank at -35.4% CAGR over 5 years.
  • Trading 27.4% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 TECH Bio-Techne Corporation SPX 51.68 73.83 $8.09B 0.62% 4.49% 5.34% 3.33% -35.38%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Mar 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Sep 2021Dec 2021Mar 2022Sep 2022Dec 2022Mar 2023Sep 2023Dec 2023Mar 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ---------144.61M154.15M163.97M-162.97M174.51M184.86M-183.24M184.93M194.68M-204.20M224.25M243.55M257.72M269.28M290.38M269.65M271.58M294.15M276.94M272.60M303.43M289.46M297.03M316.18M316.96M286.56M295.88M311.42M
Cost of Revenue -----------------------------------101.62M118.15M98.44M104.60M103.13M
Gross Profit 79.38M75.39M81.59M89.99M-87.34M88.14M96.68M-97.87M101.83M110.26M-107.60M113.02M124.61M-118.41M121.40M130.06M-137.73M150.90M168.27M171.00M183.69M201.46M179.59M183.36M202.16M185.19M176.59M204.60M183.02M193.89M214.56M198.81M188.11M191.28M208.29M
Operating Expenses -----------------------------------175.85M82.12M140.45M136.82M132.79M
Operating Income 39.43M31.03M36.02M43.53M-29.16M17.88M33.50M-26.03M24.15M43.08M-25.76M33.60M44.09M-33.33M36.99M47.79M-49.09M50.99M68.63M63.22M62.35M90.45M56.32M67.89M80.21M55.86M38.00M67.00M39.99M47.42M38.71M116.69M47.66M54.46M75.50M
EBITDA -----------------------------------67.85M6.43M75.27M77.66M97.80M
Interest Expense -----------------------------------2.01M2.18M2.93M2.17M2.40M
Pretax Income -----------------------------------38.27M-22.86M47.99M50.78M71.22M
Tax Provision -----------------------------------15.69M-5.18M9.81M12.78M20.18M
Net Income 24.29M22.71M25.85M30.29M25.63M18.84M7.47M22.17M27.61M15.86M48.85M19.74M41.70M17.40M17.56M44.65M16.46M14.40M119.62M36.43M58.85M33.40M46.27M45.78M69.61M80.17M60.74M89.56M50.01M70.22M50.99M27.46M49.06M33.60M34.89M22.59M-17.68M38.19M38.01M51.05M
Diluted EPS 0.650.610.690.810.690.500.200.590.740.421.290.521.070.450.451.150.420.373.020.921.480.831.151.121.690.490.370.550.310.430.310.170.310.210.220.14-0.110.240.240.32

Profit & Loss (Annual)

Figures in USD.

Metric Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Revenue --------563.00M642.99M714.01M738.69M931.03M1.11B1.14B1.16B1.22B
Cost of Revenue -------------349.10M366.89M389.33M429.36M
Gross Profit 208.03M214.15M224.94M235.80M231.11M251.41M307.28M336.66M374.54M432.14M473.49M483.19M632.85M756.50M769.82M769.73M790.27M
Operating Expenses -------------460.67M478.82M523.32M547.47M
Operating Income 150.78M156.33M163.06M166.21M158.47K159.75M147.02M150.59M120.58M136.18M146.72M157.42M237.30M295.83M291.00M246.40M242.80M
EBITDA -------------413.76M457.11M313.14M216.88M
Interest Expense -------------11.31M11.21M15.74M8.51M
Pretax Income -------------301.39M338.66M185.69M98.46M
Tax Provision -------------38.29M53.22M17.58M25.06M
Net Income 105.24M109.78M112.30M112.33M112.56M110.95M107.73M104.48M76.09M126.15M96.07M229.30M140.41M272.05M285.26M168.10M73.40M
Diluted EPS 2.782.943.023.043.053.002.892.802.033.312.475.820.871.661.761.050.46

Compounded Sales Growth

5 Years:3.33%
1 Year:-1.50%

Compounded Profit Growth

5 Years:-35.38%
1 Year:128.60%

Stock Price Performance

1 Year:+7.42%
6 Months:-21.27%
3 Months:-12.24%
1 Month:-0.34%

Balance Sheet (Annual)

Figures in USD.

Metric Jun 2008Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Total Assets -472.00M518.82M617.67M719.32M778.10M862.49M1.06B1.13B1.56B1.59B1.88B2.03B-2.29B2.64B2.70B2.56B
Current Assets --------------605.56M621.48M617.42M608.30M
Cash & Equivalents 166.99M160.94M94.14M77.61M116.67M163.79M318.57M54.53M64.24M91.61M121.99M100.89M146.62M-172.57M180.57M151.79M162.19M
Inventory --------------141.12M171.64M179.73M189.45M
Receivables --------------194.55M218.47M241.39M206.88M
Total Liabilities --------------593.79M672.18M635.02M639.06M
Current Liabilities --17.02M18.19M35.75M32.08M26.39M39.77M54.15M135.52M79.51M101.98M106.67M-176.02M128.51M159.38M175.85M
Long Term Debt --------------243.41M350.00M319.00M346.00M
Total Debt --------------325.97M454.96M419.54M444.06M
Total Equity 487.13M456.48M501.79M586.12M674.44M737.54M795.26M846.93M879.28M949.63M1.08B1.17B1.38B-1.70B1.97B2.07B1.92B
Shares Outstanding --------------156.64M157.64M158.22M154.97M

Cash Flows (Annual)

Figures in USD.

Metric Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Operating Cash Flow 111.32M111.26M127.19M126.75M123.56M--144.16M143.72M170.37M181.62M205.22M-325.27M254.39M298.98M287.56M
Investing Cash Flow 21.28M-114.61M-114.19M-21.67M-31.20M---107.57M-305.95M-38.71M-336.80M27.09M--96.85M-265.65M-203.03M-35.18M
Financing Cash Flow -119.44M-50.51M-36.29M-64.62M-44.68M---23.37M189.11M-99.19M134.38M-183.80M--242.85M22.62M-122.40M-253.91M
Capital Expenditure -6.56M-4.64M-3.63M-6.02M-22.45M-13.82M-19.91M-16.90M-15.18M-20.93M-25.41M-51.74M--44.91M-38.24M-62.88M-31.01M
Free Cash Flow 104.77M106.62M123.56M120.73M101.11M--127.26M128.54M149.43M156.21M153.47M-280.36M216.15M236.10M256.55M
Net Change in Cash --------------14.43M11.36M-26.45M-1.53M
Share Buybacks 90.63M14.97M1.94M23.60M1.82M00--015.40M50.11M43.18M160.95M19.56M80.04M275.73M

Ratios (Annual)

Figures in %.

Metric Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Gross Margin % --------66.5%67.2%66.3%65.4%68.0%68.4%67.7%66.4%64.8%
Operating Margin % --------21.4%21.2%20.5%21.3%25.5%26.8%25.6%21.3%19.9%
Net Margin % --------13.5%19.6%13.5%31.0%15.1%24.6%25.1%14.5%6.0%
ROE % 23.1%21.9%19.2%16.7%15.3%14.0%12.7%11.9%8.0%11.7%8.2%16.6%-16.0%14.5%8.1%3.8%
ROCE % -31.2%27.2%24.3%0.0%19.1%14.4%14.0%8.5%9.0%8.2%8.2%-14.0%11.6%9.7%10.2%

Shareholding Pattern

Insiders
0.30%
Institutions
117.81%
Public Float
118.17%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 7.83% 12.26M $633.83M
2 Vanguard Capital Management LLC 6.50% 10.18M $526.09M
3 Morgan Stanley 5.45% 8.53M $440.98M
4 FMR, LLC 5.05% 7.90M $408.27M
5 Vanguard Portfolio Management LLC 4.14% 6.48M $334.90M
6 State Street Corporation 3.75% 5.87M $303.28M
7 Wellington Management Group, LLP 3.27% 5.12M $264.61M
8 Geode Capital Management, LLC 3.27% 5.11M $264.21M
9 Maverick Capital Ltd. 3.03% 4.74M $244.95M
10 Invesco Ltd. 2.93% 4.59M $237.14M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TECH

The Verge AI 2026-05-29 10:32

How one founder’s bet on ‘the old school web’ is paying off

Craig Campbell walked away from the river of investor money flowing into AI to create, of all things, a website. Sure, Campbell probably could have started an AI company. He's a former engineer at Met…

The Verge AI 2026-05-29 13:37

Tech companies desperately want to film you doing chores

This week, an AI training startup called Shift said it would clean New Yorkers' homes for free. It has plans to expand into other cities as well, including London, and looking around my flat, I get th…

MIT Technology Review hu, 28 May 2026

The Download: climate tech goes public and the AI Hype Index returns

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. Climate tech companies are going public. What’s ne…

MIT Technology Review hu, 28 May 2026

Climate tech companies are going public. What’s next?

This year, there’s been a wave of notable energy companies going public via IPO in the US. The solar and battery company Solv Energy went public in February, to the tune of $6 billion. X-energy, which…

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks